Search
01/08/2022
The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents
Atenza, CZ, Anguera, G, Melia, MR, De Lamo, LA, Sullivan, I, Joaquin, AB, Lopez, JS, Ortiz, MA, Mulet, M, Vidal, S, Majem, M. The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2022; 71(8)DOI:10.1007/s00262-021-03107-y. PMID:34984538. IF:5.800(Q1/3D).
01/08/2022
Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia
Ramos-Muntada, M, Trincado, JL, Blanco, J, Bueno, C, Rodriguez-Cortez, VC, Bataller, A, Lopez-Millan, B, Schwab, C, Ortega, M, Velasco, P, Blanco, ML, Nomdedeu, J, Ramirez-Orellana, M, Minguela, A, Fuster, JL, Cuatrecasas, E, Camos, M, Ballerini, P, Escherich, G, Boer, J, DenBoer, M, Hernandez-Rivas, JM, Calasanz, MJ, Cazzaniga, G, Harrison, CJ, Menendez, P, Molina, O. Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia. Molecular Oncology. 2022; 16(16)DOI:10.1002/1878-0261.13276. PMID:35726693. IF:6.600(Q1/3D).
01/08/2022
Concordance of p16(INK4a) and E6*I mRNA among HPV-DNA-Positive Oropharyngeal, Laryngeal, and Oral Cavity Carcinomas from the ICO International Study
Mena, M, Wang, X, Tous, S, Quiros, B, Clavero, O, Alejo, M, Morey, F, Taberna, M, Vintro, XL, Rubio, BL, Alos, L, Mehanna, H, Quint, W, Pawlita, M, Tommasino, M, Pavon, MA, Munoz, N, De Sanjose, S, Bosch, FX, Alemany, L. Concordance of p16(INK4a) and E6*I mRNA among HPV-DNA-Positive Oropharyngeal, Laryngeal, and Oral Cavity Carcinomas from the ICO International Study. Cancers. 2022; 14(15)DOI:10.3390/cancers14153787. PMID:35954451. IF:5.200(Q2/3D).
01/08/2022
Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan
Guijarro, F, Bataller, A, Diaz-Beya, M, Garrido, A, Coll-Ferra, C, Vives, S, Salamero, O, Valcarcel, D, Tormo, M, Arnan, M, Sampol, A, Castano-Diez, S, Martinez, C, Suarez-Lledo, M, Fernandez-Aviles, F, Hernandez-Boluda, JC, Ribera, JM, Rovira, M, Brunet, S, Sierra, J, Esteve, J. Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. BONE MARROW TRANSPLANTATION. 2022; 57(8)DOI:10.1038/s41409-022-01703-9. PMID:35643942. IF:4.800(Q1/2D).
01/08/2022
TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype
Ramos-Campoy, S, Puiggros, A, Kamaso, J, Bea, S, Bougeon, S, Larrayoz, MJ, Costa, D, Parker, H, Rigolin, GM, Blanco, ML, Collado, R, Ancin, I, Salgado, R, Moro-Garcia, MA, Baumann, T, Gimeno, E, Moreno, C, Salido, M, Calvo, X, Calasanz, MJ, Cuneo, A, Nguyen-Khac, F, Oscier, D, Haferlach, C, Strefford, JC, Schoumans, J, Espinet, B. TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype. Cancers. 2022; 14(15)DOI:10.3390/cancers14153715. PMID:35954380. IF:5.200(Q2/3D).
01/08/2022
Medical education, specialty training, and emergency medicine: when the whole is more than the sum of its parts
Campmany, MP, Montiel-Dacosta, JA, Higa-Sansone, JL, Romeu, JR. Medical education, specialty training, and emergency medicine: when the whole is more than the sum of its parts. EMERGENCIAS. 2022; 34(4)DOI:. PMID:35833772. IF:5.500(Q1/2D).